pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 30·1 min read
save

Endpoints Weekly previews ASCO coverage, discusses AI in research and shifting immunotherapy strategies

May 30, 2026·read at Endpoints ↗Neutral

The weekly newsletter returns with a team of reporters stationed in Chicago for the upcoming ASCO meeting. It promises on‑the‑ground insights from the conference.

One focus will be the role of artificial intelligence in scientific research, questioning whether AI can truly drive discovery.

The editorial also notes that the earlier optimism around a single "magic bullet" in immunotherapy has faded, reflecting a more nuanced view of the field.

Readers are invited to sign up for free limited access or become premium subscribers for full articles and newsletters.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Can AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and more”

read at Endpoints ↗
90 words · retrieved Jun 2
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoExclusive: Astellas partners with Boston ‘miniproteins’ startupEndpoints
  • 2h agoRapport says drug it licensed from J&J clears Phase 2 bipolar mania studyEndpoints
  • 18h agoFormer MIT professor David Sabatini awarded $6M in defamation caseEndpoints
  • 18h agoAntheia gets $80M conditional DOD loan to onshore to the USEndpoints
  • 20h ago#ESMO26 regular abstracts featuring Zai Lab, GSK, Merck and moreEndpoints